ICL announced on April 21, 2025, the signing of a definitive agreement to acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of this transaction, ICL will also acquire Evogene's MicroBoost AI for AG platform, a computational engine for microbial product development.
Lavie Bio specializes in improving agriculture productivity and sustainability through microbiome-based ag-biological products. This acquisition is expected to position ICL as a global powerhouse in ag biologicals, integrating Lavie Bio's innovative capabilities with ICL's R&D expertise and global network.
The transaction is anticipated to close during the second quarter of 2025, subject to customary closing conditions. This strategic move enhances ICL's end-to-end innovation pipeline and reinforces its role in advancing sustainable agriculture at scale, offering differentiated, high-value products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.